|
1
|
Andersen V, Ostergaard M, Christensen J,
et al: Polymorphisms in the xenobiotic transporter Multidrug
Resistance 1 (MDR1) and interaction with meat intake in relation to
risk of colorectal cancer in a Danish prospective case-cohort
study. BMC Cancer. 9:4072009. View Article : Google Scholar
|
|
2
|
Chen P, Zhao L, Zou P, et al: The
contribution of the ABCG2 C421A polymorphism to cancer
susceptibility: A meta-analysis of the current literature. BMC
Cancer. 12:3832012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dietrich CG, Vehr AK, Martin IV, et al:
Downregulation of breast cancer resistance protein in colon
adenomas reduces cellular xenobiotic resistance and leads to
accumulation of a food-derived carcinogen. Int J Cancer.
129:546–552. 2011. View Article : Google Scholar
|
|
4
|
Guengerich FP: Metabolism of chemical
carcinogens. Carcinogenesis. 21:345–351. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shiloh Y: ATM and related protein kinases:
Safeguarding genome integrity. Nat Rev Cancer. 3:155–168. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dietrich CG, Geier A and Oude Elferink RP:
ABC of oral bioavailability: Transporters as gatekeepers in the
gut. Gut. 52:1788–1795. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Klein I, Sarkadi B and Varadi A: An
inventory of the human ABC proteins. Biochim Biophys Acta.
1461:237–262. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Velamakanni S, Wei SL, Janvilisri T, et
al: ABCG transporters: Structure, substrate specificities and
physiological roles: A brief overview. J Bioenerg Biomembr.
39:465–471. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Allikmets R, Schriml LM, Hutchinson A, et
al: A human placenta-specific ATP-binding cassette gene (ABCP) on
chromosome 4q22 that is involved in multidrug resistance. Cancer
Res. 58:5337–5339. 1998.PubMed/NCBI
|
|
10
|
Doyle LA, Yang W, Abruzzo LV, et al: A
multidrug resistance transporter from human MCF-7 breast cancer
cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Isshiki M, Umezawa K and Tamura H: Coffee
induces breast cancer resistance protein expression in Caco-2
cells. Biol Pharm Bull. 34:1624–1627. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lockhart AC, Tirona RG and Kim RB:
Pharmacogenetics of ATP-binding cassette transporters in cancer and
chemotherapy. Mol Cancer Ther. 2:685–698. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Staud F and Pavek P: Breast cancer
resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol.
37:720–725. 2005. View Article : Google Scholar
|
|
14
|
Campa D, Pardini B, Naccarati A, et al: A
gene-wide investigation on polymorphisms in the ABCG2/BRCP
transporter and susceptibility to colorectal cancer. Mutat Res.
645:56–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ebert B, Seidel A and Lampen A:
Identification of BCRP as transporter of benzo[a]pyrene conjugates
metabolically formed in Caco-2 cells and its induction by
Ah-receptor agonists. Carcinogenesis. 26:1754–1763. 2005.
View Article : Google Scholar
|
|
16
|
Gupta N, Martin PM, Miyauchi S, et al:
Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.
Biochem Biophys Res Commun. 343:571–577. 2006. View Article : Google Scholar
|
|
17
|
Jonker JW, Buitelaar M, Wagenaar E, et al:
The breast cancer resistance protein protects against a major
chlorophyll-derived dietary phototoxin and protoporphyria. Proc
Natl Acad Sci USA. 99:15649–15654. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pavek P, Merino G, Wagenaar E, et al:
Human breast cancer resistance protein: Interactions with steroid
drugs, hormones, the dietary carcinogen
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of
cimetidine. J Pharmacol Exp Ther. 312:144–152. 2005. View Article : Google Scholar
|
|
19
|
Compton CC and Greene FL: The staging of
colorectal cancer: 2004 and beyond. CA Cancer J Clin. 54:295–308.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krishnamurthy P and Schuetz JD: Role of
ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol.
46:381–410. 2006. View Article : Google Scholar
|
|
21
|
Maliepaard M, Scheffer GL, Faneyte IF, et
al: Subcellular localization and distribution of the breast cancer
resistance protein transporter in normal human tissues. Cancer Res.
61:3458–3464. 2001.PubMed/NCBI
|
|
22
|
Mao Q and Unadkat JD: Role of the breast
cancer resistance protein (ABCG2) in drug transport. AAPS J.
7:E118–E133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Muller P, Asher N, Heled M, et al:
Polymorphisms in transporter and phase II metabolism genes as
potential modifiers of the predisposition to and treatment outcome
of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk
Res. 32:919–929. 2008. View Article : Google Scholar
|
|
24
|
Sarkadi B, Ozvegy-Laczka C, Nemet K, et
al: ABCG2 - a transporter for all seasons. FEBS Lett. 567:116–120.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schinkel AH and Jonker JW: Mammalian drug
efflux transporters of the ATP binding cassette (ABC) family: An
overview. Adv Drug Deliv Rev. 55:3–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dai D, Zeldin DC, Blaisdell JA, et al:
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer
drug paclitaxel and arachidonic acid. Pharmacogenetics. 11:597–607.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eisenblatter T and Galla HJ: A new
multidrug resistance protein at the blood-brain barrier. Biochem
Biophys Res Commun. 293:1273–1278. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jonker JW, Smit JW, Brinkhuis RF, et al:
Role of breast cancer resistance protein in the bioavailability and
fetal penetration of topotecan. J Natl Cancer Inst. 92:1651–1656.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jonker JW, Merino G, Musters S, et al: The
breast cancer resistance protein BCRP (ABCG2) concentrates drugs
and carcinogenic xenotoxins into milk. Nat Med. 11:127–129. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Korenaga Y, Naito K, Okayama N, et al:
Association of the BCRP C421A polymorphism with nonpapillary renal
cell carcinoma. Int J Cancer. 117:431–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kruijtzer CM, Beijnen JH, Rosing H, et al:
Increased oral bioavailability of topotecan in combination with the
breast cancer resistance protein and P-glycoprotein inhibitor
GF120918. J Clin Oncol. 20:2943–2950. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haimeur A, Conseil G, Deeley RG, et al:
The MRP-related and BCRP/ABCG2 multidrug resistance proteins:
Biology, substrate specificity and regulation. Curr Drug Metab.
5:21–53. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zamber CP, Lamba JK, Yasuda K, et al:
Natural allelic variants of breast cancer resistance protein (BCRP)
and their relationship to BCRP expression in human intestine.
Pharmacogenetics. 13:19–28. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kondo C, Suzuki H, Itoda M, et al:
Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res.
21:1895–1903. 2004. View Article : Google Scholar
|
|
35
|
Mizuarai S, Aozasa N and Kotani H: Single
nucleotide polymorphisms result in impaired membrane localization
and reduced ATPase activity in multidrug transporter ABCG2. Int J
Cancer. 109:238–246. 2004. View Article : Google Scholar
|
|
36
|
Liu HG, Pan YF, You J, et al: Expression
of ABCG2 and its significance in colorectal cancer. Asian Pac J
Cancer Prev. 11:845–848. 2010.PubMed/NCBI
|
|
37
|
Hu LL, Wang XX, Chen X, et al: BCRP gene
polymorphisms are associated with susceptibility and survival of
diffuse large B-cell lymphoma. Carcinogenesis. 28:1740–1744. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pollex EK, Anger G, Hutson J, et al:
Breast cancer resistance protein (BCRP)-mediated glyburide
transport: Effect of the C421A/Q141K BCRP single-nucleotide
polymorphism. Drug Met Dispos. 38:740–744. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
de Jong FA, Marsh S, Mathijssen RH, et al:
ABCG2 pharmacogenetics: Ethnic differences in allele frequency and
assessment of influence on irinotecan disposition. Clin Cancer Res.
10:5889–5894. 2004.PubMed/NCBI
|
|
40
|
Imai Y, Nakane M, Kage K, et al: C421A
polymorphism in the human breast cancer resistance protein gene is
associated with low expression of Q141K protein and low-level drug
resistance. Mol Cancer Ther. 1:611–616. 2002.PubMed/NCBI
|
|
41
|
Kobayashi D, Ieiri I, Hirota T, et al:
Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein
expression in human placenta. Drug Metab Dispos. 33:94–101. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Itoda M, Saito Y, Shirao K, et al: Eight
novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese
cancer patients administered irinotecan. Drug Metab Pharmacokinet.
18:212–217. 2003. View Article : Google Scholar
|
|
43
|
Backstrom G, Taipalensuu J, Melhus H, et
al: Genetic variation in the ATP-binding cassette transporter gene
ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci. 18:359–364.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Noguchi K, Katayama K, Mitsuhashi J, et
al: Functions of the breast cancer resistance protein (BCRP/ABCG2)
in chemotherapy. Adv Drug Deliv Rev. 61:26–33. 2009. View Article : Google Scholar
|
